SCHEMBL20284482

SCHEMBL20284482

CNC(=O)COc1cc2cc(N)ccc2n(C(C)C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ BCL6 P41182 7/20 0.41
▸ MELK Q14680 1/20 0.40
▸ NCOR2 Q9Y618 4/20 0.40
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NTSR1 P30989 1/20 0.36
▸ BRPF1 P55201 1/20 0.36
▸ PDE4B Q07343 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ F2 P00734 1/20 0.34
▸ PRSS1 P07477 1/20 0.34
▸ PRSS2 P07478 1/20 0.34
▸ PRSS3 P35030 1/20 0.34
▸ KLKB1 P03952 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ NPY5R Q15761 1/20 0.33
▸ ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23267980 0.87 BCHE (0.45) BCHEACHEBCL6MELKNCOR2
SCHEMBL20267767 0.85 BCL6 (0.54) BCHEACHEBCL6MELKNCOR2
SCHEMBL20284358 0.83 BCL6 (0.42) BCHEACHEBCL6MELKNCOR2
SCHEMBL29873889 0.83 BCL6 (0.42) BCHEACHEBCL6MELKNCOR2
SCHEMBL21787570 0.83 MAPT (0.45) BCHEACHEBCL6ALDH1A1SMN1; SMN2
SCHEMBL23267393 0.83 BCL6 (0.43) BCHEACHEBCL6MELKNCOR2
SCHEMBL23267404 0.82 BCL6 (0.42) BCHEACHEBCL6MELKNCOR2
SCHEMBL23267876 0.82 BRPF1 (0.41) ALDH1A1SMN1; SMN2BRPF1KMT2ANPC1
SCHEMBL21787572 0.81 KDM4E (0.38) ALDH1A1NTSR1BRPF1LMNAKMT2A
SCHEMBL29061114 0.81 BCL6 (0.36) BCHEACHEBCL6MELKNCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605387-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-08-27 — — EP disclosed
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-05-27 — — US disclosed
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-10-03 — — US disclosed
US-20240190841-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-06-13 — — US disclosed
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-21 — — US disclosed
WO-2024086759-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-04-25 — — WO disclosed
EP-4323352-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-02-21 — — EP disclosed
CN-117279910-A Modulators of BCL6 proteolysis and related methods of use 阿尔维纳斯运营股份有限公司 2023-12-22 — — CN disclosed
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 — — US disclosed
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 — — US disclosed
CN-115397821-A Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2022-11-25 — — CN disclosed
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-13 — — US disclosed
EP-4045496-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY Arvinas Operations, Inc. (US) 2022-08-24 — — EP disclosed
US-11001570-B2 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-05-11 — — US disclosed
WO-2021077010-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY ARVINAS OPERATIONS, INC. (US) 2021-04-22 — — WO disclosed
WO-2021077010-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY ARVINAS OPERATIONS, INC. (US) 2021-04-22 — — WO disclosed
EP-3555063-B1 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-09-16 — — EP disclosed
US-20200071297-A1 NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2020-03-05 — — US disclosed
WO-2018108704-A1 NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 BCHE 1649/4885ACHE 4604/4885BCL6 1/4885
US-20240190841-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 BCHE 1620/4885ACHE 4523/4885BCL6 1/4885
US-11986532-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 BCHE 1380/4885ACHE 4373/4885BCL6 1/4885
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 BCHE 1649/4885ACHE 4604/4885BCL6 1/4885
US-20200071297-A1 NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS BCL6, BCL6B, BCOR BCHE 3873/4885ACHE 4841/4885BCL6 1/4885
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 BCHE 1380/4885ACHE 4373/4885BCL6 1/4885
US-11001570-B2 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors BCL6, BCL6B, BCOR BCHE 3625/4885ACHE 4799/4885BCL6 1/4885
US-20240325547-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 BCHE 1380/4885ACHE 4373/4885BCL6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback